Lilly and Boehringer roll toward EU approval with diabetes combo

Eli Lilly ($LLY) and Boehringer Ingelheim secured a recommendation from European regulators for their combination diabetes treatment, making for a likely continental approval in the coming months. The drug is a fixed-dose combination of empagliflozin, an SGLT-2 inhibitor that forces excess blood sugars out through the urine, and metformin, a long-generic treatment designed to block glucose production in the liver. The pair plans to market the combination as Synjardy, expecting to pick up FDA approval later this year. Empagliflozin won approval last year and is marketed as Jardiance. More

Suggested Articles

Two months of treatment with the diabetes drug Jardiance reduced pulmonary congestion and biomarkers of heart failure in pig models.

Neither dose of the NGF inhibitor hit all the co-primary efficacy goals, and both fared worse than placebo on the safety assessments.

Mustang Bio’s stock leapt more than 400% before settling down, on the news that its gene therapy cured eight infants with “bubble boy” syndrome.